Browse News
Filter News
Found 182 articles
-
Nimbus Therapeutics Presents Additional Clinical Data from Phase 1 Studies of Oral Allosteric TYK2 Inhibitor at SID Annual Meeting
5/19/2022
Nimbus Therapeutics , a clinical-stage company that is working to design and develop breakthrough medicines through its powerful computational drug discovery engine, today announced the presentation of new data from multiple Phase 1 clinical studies of its investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor, NDI-034858, in both healthy volunteers and patients with moderate-to-severe psoriasis.
-
Nimbus Therapeutics Strengthens Clinical Development Leadership Team
4/13/2022
Nimbus Therapeutics today announced the expansion of its leadership team with the appointments of Zak Huang as Vice President, Regulatory Affairs, and Gabrielle Poirier as Vice President, Clinical Operations.
-
Nimbus Therapeutics Presents Preclinical Data on Cbl-b Inhibitor at AACR Annual Meeting
4/8/2022
Nimbus Therapeutics, a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, is sharing preclinical data, released today, on its Casitas B-lineage lymphoma b (Cbl-b) inhibitor, NTX-801, at the American Association for Cancer Research (AACR) 2022 Annual Meeting, being held April 8-13, 2022, in New Orleans, LA.
-
AstraZeneca has penned a deal with Harbour Biomed for its bispecific antibody HBM7022, which is intended to eliminate tumors in oncological patients.
-
AstraZeneca will showcase its early oncology portfolio at the American Association for Cancer Research set to begin on April 8.
-
The 2022 American Academy of Dermatology Annual Meeting saw several milestones for treatment explorations for inflammatory diseases. Here is some of the major news:
-
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
-
Nimbus Therapeutics to Present Update on Cbl-b Discovery Program at AACR 2022 Annual Meeting
3/28/2022
Nimbus Therapeutics today announced that it will present preclinical data from its Casitas B-lineage lymphoma b (Cbl-b) program at the American Association for Cancer Research (AACR) 2022 Annual Meeting, being held April 8-13, 2022 in New Orleans, LA.
-
Nimbus Therapeutics Presents Clinical Data from Phase 1b Study of Oral Allosteric TYK2 Inhibitor at AAD Annual Meeting
3/25/2022
Nimbus Therapeutics today presented data from the Phase 1b clinical trial of its investigational oral allosteric tyrosine kinase 2 (“TYK2”) inhibitor, NDI-034858, in patients with moderate-to-severe plaque psoriasis at the 2022 American Academy of Dermatology (AAD) Annual Meeting.
-
Schrödinger Reports Financial Results for the Fourth Quarter and Full Year 2021
2/24/2022
Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, announced financial results for the fourth quarter and full year ended December 31, 2021, and provided its financial outlook for 2022.
-
Computational Biology Market Size to Reach USD 16.58 Billion in 2027 | Industry Trend – Rapid Advancements and Growth in the Field of Computational Biology
2/10/2022
Computational biology is an integrated approach that employs high performance computers, state-of-the-art software and algorithms, statistical analysis, and mathematical modeling to uncover and identify the complexity of biological systems.
-
Nimbus Therapeutics Shares Update on Discovery Efforts in Computational Chemistry, Expands Leadership Team
2/3/2022
Nimbus Therapeutics today announced the successful generation of multiple, high-resolution protein structures of Werner syndrome helicase (WRN).
-
Nimbus Therapeutics Announces Expansion of Oral Allosteric TYK2 Inhibitor Program and Provides Additional Business Updates
1/6/2022
Nimbus Therapeutics today announced initiation of a Phase 2b study of the company’s investigational oral allosteric TYK2 inhibitor in patients with active psoriatic arthritis.
-
Nimbus Therapeutics Announces First Patient Dosed in Phase 1/2 Study of a Highly Selective HPK1 Inhibitor in Patients with Solid Tumors
11/12/2021
Nimbus Therapeutics today announced the first patient dosed in the first-in-human Phase 1/2 study of their small-molecule hematopoietic progenitor kinase 1 (HPK1) inhibitor, NDI-101150.
-
Life Sciences BC Announces Presenting Companies Pitching at Invest in BC Presented by Lumira Ventures
10/15/2021
Life Sciences British Columbia (LSBC) announces the 31 companies presenting to the 6th annual Invest in BC presented by Lumira Ventures on November 3 and 4, 2021
-
Nimbus Therapeutics Publishes Structural Analysis Highlighting Mechanisms for Selective Inhibition of CTPS1
9/30/2021
Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, today published research in the Proceedings of the National Academy of Sciences describing the structural basis for isoform-specific inhibition of human CTPS1 (CTP synthase 1).
-
Ajax Therapeutics Expands Management Team to Support Advancement of Novel Therapies for Hematologic Malignancies
9/29/2021
Ajax Therapeutics, Inc. today announced the company has expanded its leadership team
-
BioSpace Movers & Shakers, Sept. 24
9/24/2021
Life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers. -
Nimbus Therapeutics Appoints Ian Sanderson, MBA, as Chief Financial Officer
9/21/2021
Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, announced the appointment of Ian Sanderson, MBA, as Chief Financial Officer.
-
BioSpace Movers & Shakers, Sept. 17
9/17/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.